Clinical trials
Phase 4 Pulmonary Disease, Chronic Obstructive trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 15 |
| Completed | 13 |
| Recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Zhujiang Hospital | 4 |
| Boehringer Ingelheim | 3 |
| China National Biotec Group Company Limited | 3 |
| The First Affiliated Hospital of Guangzhou Medical University | 3 |
| AstraZeneca | 2 |
| Bayer | 1 |
| Capital Medical University | 1 |
| Chinese PLA General Hospital | 1 |
| Daiichi Sankyo | 1 |
| Fudan University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Disease, Chronic Obstructive | 31 |
| Bronchitis, Chronic | 5 |
| COVID-19 | 3 |
| Bronchiectasis | 2 |
| Invasive Pulmonary Aspergillosis | 2 |
| Lung Diseases | 2 |
| Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome | 1 |
| Bronchitis | 1 |
| Emphysema | 1 |
| Lung Diseases, Obstructive | 1 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.